We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company’s adjusted earnings per share of 45 cents beat the Zacks Consensus Estimate by 21.6%. Over the trailing four quarters, its earnings topped the Zacks Consensus Estimate on three occasions, and missed once, delivering an earnings surprise of 16.1%, on average.
Year to date, BTSG’s shares have rallied 58.8%, outperforming the broader Zacks Medical Services Market, which has gained 8.4%, and the S&P 500, which has risen 12%.
Image Source: Zacks Investment Research
Factors Likely to Shape BTSG’s Q3 Results
Specialty and Infusion Growth: Strong momentum in Specialty and Infusion Services is likely to have supported BrightSpring Health Services’ third-quarter performance. In the second quarter, the segment’s revenues grew 30% year over year, supported by branded limited-distribution drugs (LDDs), new launches, generic conversions, fee-for-service programs and infusion growth. Management expects sequential growth throughout the second half, with recently launched LDDs, including new oncology and rare-disease therapies, likely to have contributed to revenue and gross profit growth. Continued generic growth and expanding infusion volumes may also have supported profitability.
Provider Services: Strong demand for home-based care and continued operational improvements are likely to have supported Provider Services. Second-quarter revenues increased 30%, while Home Health Care revenues rose 51%, reflecting census growth, de novo expansions and contributions from the acquired Amedisys and LHC branches. Management indicated that the acquired branches were performing ahead of plan, with further margin improvement expected as integration progresses. Continued growth in rehabilitation and personal care services may also have contributed to the segment’s performance.
Profitability and Cost Efficiencies: Continued lean initiatives, automation and technology investments are likely to have supported margins. In the second quarter, adjusted EBITDA increased 44% year over year, while the company’s adjusted EBITDA margin expanded 80 basis points. Management expects these efficiency initiatives, alongside favorable generic-drug trends and operating leverage from higher volumes, to support continued growth. Gross profit per script is likely to have remained stable or improved slightly, although business mix may have influenced the outcome.
IRA Headwinds: Home and Community Pharmacy is likely to have remained under pressure from the Inflation Reduction Act (IRA) and the exit of certain uneconomic customers. Management expects the IRA to reduce revenues by approximately $45 million in the third quarter of 2026. Although operational efficiencies may have supported the business’ profitability, IRA-related pressure may have remained an offsetting factor.
BTSG’s Estimate Picture
For third-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $3.86 billion, implying an improvement of 15.8% from the prior-year quarter’s reported figure.
The consensus estimate for adjusted earnings per share is pegged at 49 cents, indicating growth of 63.3% from the prior-year period’s reported number.
BrightSpring Health Services, Inc. Price and EPS Surprise
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see below.
BrightSpring’s Earnings ESP: BTSG has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank of BTSG: The company currently carries a Zacks Rank #3.
Stocks to Consider
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) currently has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, currently has an Earnings ESP of +0.21% and a Zacks Rank #2. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?
Key Takeaways
BrightSpring Health Services, Inc. (BTSG - Free Report) is scheduled to report third-quarter 2026 results on Oct. 30, before market hours.
In the last reported quarter, the company’s adjusted earnings per share of 45 cents beat the Zacks Consensus Estimate by 21.6%. Over the trailing four quarters, its earnings topped the Zacks Consensus Estimate on three occasions, and missed once, delivering an earnings surprise of 16.1%, on average.
Year to date, BTSG’s shares have rallied 58.8%, outperforming the broader Zacks Medical Services Market, which has gained 8.4%, and the S&P 500, which has risen 12%.
Image Source: Zacks Investment Research
Factors Likely to Shape BTSG’s Q3 Results
Specialty and Infusion Growth: Strong momentum in Specialty and Infusion Services is likely to have supported BrightSpring Health Services’ third-quarter performance. In the second quarter, the segment’s revenues grew 30% year over year, supported by branded limited-distribution drugs (LDDs), new launches, generic conversions, fee-for-service programs and infusion growth. Management expects sequential growth throughout the second half, with recently launched LDDs, including new oncology and rare-disease therapies, likely to have contributed to revenue and gross profit growth. Continued generic growth and expanding infusion volumes may also have supported profitability.
Provider Services: Strong demand for home-based care and continued operational improvements are likely to have supported Provider Services. Second-quarter revenues increased 30%, while Home Health Care revenues rose 51%, reflecting census growth, de novo expansions and contributions from the acquired Amedisys and LHC branches. Management indicated that the acquired branches were performing ahead of plan, with further margin improvement expected as integration progresses. Continued growth in rehabilitation and personal care services may also have contributed to the segment’s performance.
Profitability and Cost Efficiencies: Continued lean initiatives, automation and technology investments are likely to have supported margins. In the second quarter, adjusted EBITDA increased 44% year over year, while the company’s adjusted EBITDA margin expanded 80 basis points. Management expects these efficiency initiatives, alongside favorable generic-drug trends and operating leverage from higher volumes, to support continued growth. Gross profit per script is likely to have remained stable or improved slightly, although business mix may have influenced the outcome.
IRA Headwinds: Home and Community Pharmacy is likely to have remained under pressure from the Inflation Reduction Act (IRA) and the exit of certain uneconomic customers. Management expects the IRA to reduce revenues by approximately $45 million in the third quarter of 2026. Although operational efficiencies may have supported the business’ profitability, IRA-related pressure may have remained an offsetting factor.
BTSG’s Estimate Picture
For third-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $3.86 billion, implying an improvement of 15.8% from the prior-year quarter’s reported figure.
The consensus estimate for adjusted earnings per share is pegged at 49 cents, indicating growth of 63.3% from the prior-year period’s reported number.
BrightSpring Health Services, Inc. Price and EPS Surprise
BrightSpring Health Services, Inc. price-eps-surprise | BrightSpring Health Services, Inc. Quote
What Our Model Suggests About BTSG Stock
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. However, this is not the case here, as you can see below.
BrightSpring’s Earnings ESP: BTSG has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank of BTSG: The company currently carries a Zacks Rank #3.
Stocks to Consider
Here are some medical product stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Phibro Animal Health (PAHC - Free Report) has an Earnings ESP of +2.10% and carries a Zacks Rank #2 at present. The company is expected to release first-quarter fiscal 2027 results on Nov. 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company’s first-quarter EPS indicates an increase of 8.2% from the year-ago quarter’s figure.
IDEXX Laboratories (IDXX - Free Report) currently has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2.
IDXX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.1% from the year-ago quarter’s figure.
Becton, Dickinson and Company (BDX - Free Report) , or BD, currently has an Earnings ESP of +0.21% and a Zacks Rank #2. The company is set to release fourth-quarter fiscal 2026 results on Nov. 5.
BD’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter’s figure.